Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders
Salvatore D’Angelo,1 Giuseppina Tramontano,1 Michele Gilio,1 Pietro Leccese,1 Ignazio Olivieri1,2 1Rheumatology Institute of Lucania (IRel) - Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza and Matera, 2Basilicata Ricer...
Guardado en:
Autores principales: | D'Angelo S, Tramontano G, Gilio M, Leccese P, Olivieri I |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2f583fd1e7ab4b059234f1b123310e4a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Ustekinumab-induced chronic lymphocytic leukemia in a patient with psoriatic arthritis
por: Fusun Gediz, et al.
Publicado: (2021) -
Methotrexate-Related Liver Cirrhosis in Psoriatic Arthritis: A Case Report and Review of the Literature
por: Maria-Loukia Koutsompina, et al.
Publicado: (2021) -
Repository corticotropin injection in patients with refractory psoriatic arthritis: a case series
por: Brown AN
Publicado: (2016) -
An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy
por: Acosta-Felquer ML, et al.
Publicado: (2016) -
Brazilian Society of Rheumatology 2020 guidelines for psoriatic arthritis
por: Sueli Carneiro, et al.
Publicado: (2021)